A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation

Blood

Volumn 122, Issue 10, 2013, Pages 1793-1801

  Girard Pierce, Kathryn R ^a   Stowell, Sean R ^a   Smith, Nicole H ^a   Arthur, C Maridith ^a   Sullivan, Harold C ^a   Hendrickson, Jeanne E ^a   Zimring, James C ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD16 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 6; KEL2 ANTIGEN; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; ALLOANTIBODY; ANTIBODY; FC RECEPTOR; GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP KELL SYSTEM; BLOOD TRANSFUSION REACTION; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; CONTROLLED STUDY; DOWN REGULATION; ERYTHROCYTE; ERYTHROCYTE CLEARANCE; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; INTRAVASCULAR HEMOLYSIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; BLOOD GROUP INCOMPATIBILITY; C57BL MOUSE; CELL SURVIVAL; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROTEIN BINDING; TIME;

ANIMALS; ANTIBODIES; ANTIGENS; BLOOD GROUP INCOMPATIBILITY; CELL SURVIVAL; COMPLEMENT C3; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; GLYCOPROTEINS; HUMANS; IMMUNIZATION, PASSIVE; ISOANTIBODIES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN BINDING; RECEPTORS, IGG; TIME FACTORS;

EID: 84886490466     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508952     Document Type: Article

References (35)

1. Müller-Eberhard HJ. Complement. Annu Rev Biochem. 1969;38:389-414.
2. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058-1066.
3. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344(15):1140-1144.
4. Stowell SR, Winkler AM, Maier CL, et al. Initiation and regulation of complement during hemolytic transfusion reactions. Clin Dev Immunol. 2012; (2012):307093.
5. Mollison PL. The role of complement in antibodymediated red-cell destruction. Br J Haematol. 1970;18(3):249-255.
6. Müller-Eberhard HJ. The membrane attack complex of complement. Annu Rev Immunol. 1986;4:503-528.
7. Lambris JD. The multifunctional role of C3, the third component of complement. Immunol Today. 1988;9(12):387-393.
8. Meryhew NL, Runquist OA. A kinetic analysis of immune-mediated clearance of erythrocytes. J Immunol. 1981;126(6):2443-2449.
9. Engelfriet CP. The immune destruction of red cells. Transfus Med. 1992;2(1):1-6.
10. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol. 2006;118(2-3): 127-136.
11. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med. 1987;166(5):1221-1228.
12. Harrison RA, Lachmann PJ. The physiological breakdown of the third component of human complement. Mol Immunol. 1980;17(1):9-20.
13. Zimring JC, Cadwell CM, Spitalnik SL. Antigen loss from antibody-coated red blood cells. Transfus Med Rev. 2009;23(3): 189-204.
14. Bosco A, Xenocostas A, Kinney J, Cadwell CM, Zimring JC. An autoanti-Kp b immunoglobulin M that simulates antigen suppression. Transfusion. 2009;49(4):750-756.
15. Brendel WL, Issitt PD, Moore RE, et al. Temporary reduction of red cell Kell system antigen expression and transient production of anti-Kpb in a surgical patient. Biotest Bull. 1985; 2:201-206.
16. Vengelen-Tyler V, Gonzalez B, Garratty G, et al. Acquired loss of red cell Kell antigens. Br J Haematol. 1987;65(2):231-234.
17. Williamson LM, Poole J, Redman C, et al. Transient loss of proteins carrying Kell and Lutheran red cell antigens during consecutive relapses of autoimmune thrombocytopenia. Br J Haematol. 1994;87(4):805-812.
18. van't Veer MB, van Wieringen PM, van Leeuwen I, Overbeeke MA, von dem Borne AE, Engelfriet CP. A negative direct antiglobulin test with strong IgG red cell autoantibodies present in the serum of a patient with autoimmune haemolytic anaemia. Br J Haematol. 1981;49(3):383-386.
19. Marsh WL, Oyen R, Alicea E, Linter M, Horton S. Autoimmune hemolytic anemia and the Kell blood groups. Am J Hematol. 1979;7(2):155-162.
20. Seyfried H, Górska B, Maj S, Sylwestrowicz T, Giles CM, Goldsmith KL. Apparent depression of antigens of the Kell blood group system associated with autoimmune acquired haemolytic anaemia. Vox Sang. 1972;23(6):528-536.
21. Reid ME, Lomas-Francis C. The Blood Group Antigen Facts Book. 2nd ed. Amsterdam, Netherlands: Elsevier Academic Press; 2004.
22. Janatpour KA, Kalmin ND, Jensen HM, Holland PV. Clinical outcomes of ABO-incompatible RBC transfusions. Am J Clin Pathol. 2008;129(2): 276-281.
23. Smith NH, Henry KL, Cadwell CM, et al. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion. 2012;52(12): 2620-2630.
24. Stowell SR, Girard-Pierce KR, Smith NH, et al. Transfusion of murine red blood cells expressing the human KEL glycoprotein induces clinically significant alloantibodies [published online ahead of print April 29, 2013]. Transfusion.
25. Zimring JC, Hair GA, Chadwick TE, et al. Nonhemolytic antibody-induced loss of erythrocyte surface antigen. Blood. 2005;106(3): 1105-1112.
26. Zimring JC, Cadwell CM, Chadwick TE, et al. Nonhemolytic antigen loss from red blood cells requires cooperative binding of multiple antibodies recognizing different epitopes. Blood. 2007;110(6):2201-2208.
27. Westhoff CM, Reid ME. Review: the Kell, Duffy, and Kidd blood group systems. Immunohematol. 2004;20(1):37-49.
28. Moller G. Isoantibody-induced cellular resistance to immune haemolysis in vivo and in vitro. Nature. 1964;202:357-359.
29. Logue GL, Rosse WF, Gockerman JP. Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome. J Clin Invest. 1973;52(2):493-501.
30. Fong DC, Brauweiler A, Minskoff SA, et al. Mutational analysis reveals multiple distinct sites within Fc gamma receptor IIB that function in inhibitory signaling. J Immunol. 2000;165(8): 4453-4462.
31. Brauweiler AM, Cambier JC. Fc gamma RIIB activation leads to inhibition of signalling by independently ligated receptors. Biochem Soc Trans. 2003;31(Pt 1):281-285.
32. Liepkalns JS, Hod EA, Stowell SR, Cadwell CM, Spitalnik SL, Zimring JC. Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcγ receptors in a murine model. Transfusion. 2012; 52(12):2631-2645.
33. Yu J, Heck S, Debnath A, Yazdanbakhsh K. Identification of a complement receptor 1 peptide for inhibition of immune hemolysis. Biochem Biophys Res Commun. 2007;353(2): 363-368.
34. Yazdanbakhsh K. Review: complement receptor 1 therapeutics for prevention of immune hemolysis. Immunohematol. 2005;21(3): 109-118.
35. Wouters D, Stephan F, Strengers P, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013;121(7):1242-1244.